MedTrace Logo

AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors

NCT00985868 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2019-11-29

No results posted yet for this study

Summary

RATIONALE: AT9283 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of AT9283 in children and adolescents with relapsed and refractory solid tumors.

Conditions

  • Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

DRUG

multikinase inhibitor AT9283

OTHER

enzyme-linked immunosorbent assay

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

Sponsors & Collaborators

Principal Investigators

  • Darren Hargrave, MD · Great Ormond Street Hospital for Children NHS Foundation Trust

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2016-01-25
Completion
2019-11-20

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00985868 on ClinicalTrials.gov